Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Filer	Shares	Latest Filing Date	Previously owned	Change	Share-Type	Market Value
Group One Trading, L.P.	5.06K	2023-08-09	2.80K	2.26K	Shares	2.58M
Kingsbury Capital Investmen...	0	2022-11-10	25.06K	-25.06K	Shares	0

NASDAQ:ALZN

Alzamend Neuro, Inc.

Last Close

0.76

01/05 20:00

Market Cap

5.77M

Beta: -

Volume Today

39.12K

Avg: 184.60K

PE Ratio

−0.38

PFCF: −0.69

Institutional trades

Institutional Ownership

Current holdings institutionals

Please Sign In To Use The Chat